BioNTech SE

BNTX

NASDAQ. Currency in USD

168.56 -6.69 ( -3.82% )

Real time prices: December 19

Market Cap.
40.91B
Beta (5Y monthly)
0.16
Price/Earnings
3.88
EPS (TTM)
44.26
Forward Dividend
2.11 (1.13%)
Ex-Dividend Date
Jun 03, 2022
Volume
923,885
1y Target Est.
213.44
Day's Range
167.70
-
177.75
52 Week's Range
117.08
-
189.07

Historical Summary

Performance
EPS growth
Share Buybacks

About BioNTech SE

Sector
Healthcare
Industry
Biotechnology
Website
https://www.biontech.de
Exchange
NASDAQ (XNAS)
Shares Outstanding
246.81M
Employees
4000
Address
An der Goldgrube 12, Mainz, Germany, 55131
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; Regeneron Pharmaceuticals, Inc. and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Latest news

Moderna's (MRNA) BA.1 Omicron Booster Gets CHMP Nod for Kids
Moderna's (MRNA) BA.1 Omicron Booster Gets CHMP Nod for Kids

The CHMP recommends authorizing Moderna's (MRNA) bivalent COVID-19 booster vaccine, targeting the Omicron BA.1 subvariant,...
By Zacks Investment Research - 6 weeks ago

FDA Delays Decision on AstraZeneca (AZN), Merck's Lynparza sNDA
FDA Delays Decision on AstraZeneca (AZN), Merck's Lynparza sNDA

The FDA extends the review period of AstraZeneca (AZN)/Merck's filing seeking label expansion for Lynparza's...
By Zacks Investment Research - 7 weeks ago

Icosavax (ICVX) Up 112% on Upbeat Data From RSV Jab Study
Icosavax (ICVX) Up 112% on Upbeat Data From RSV Jab Study

Data from an early-stage study showed that Icosavax's (ICVX) investigational RSV vaccine exhibited sustained immunologic...
By Zacks Investment Research - 7 weeks ago

BioNTech upgraded to buy on high hopes for combined flu/COVID vaccine and oncology pipeline
BioNTech upgraded to buy on high hopes for combined flu/COVID vaccine and oncology pipeline

Bank of America turned bullish on German biotech BioNTech on Thursday
By MarketWatch - 7 weeks ago

BioNTech Stock Gets Upgrade, Analyst Sees Multiple Upside Opportunities
BioNTech Stock Gets Upgrade, Analyst Sees Multiple Upside Opportunities

BofA Securities has upgraded BioNTech SE (NASDAQ: BNTX) and maintains a $239 price target. The...
By Benzinga - 7 weeks ago

Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022

Upgrades B of A Securities upgraded the previous rating for Radian Group Inc (NYSE:RDN) from...
By Benzinga - 7 weeks ago

Wave Life Sciences (WVE) Up 26% on Collaboration With GSK
Wave Life Sciences (WVE) Up 26% on Collaboration With GSK

Wave Lifesciences (WVE) signs a four-year research collaboration with GSK to advance discovery and development...
By Zacks Investment Research - 7 weeks ago

Eli Lilly (LLY) 2023 Guidance Falls Short, Stock Declines
Eli Lilly (LLY) 2023 Guidance Falls Short, Stock Declines

Eli Lilly's (LLY) 2023 EPS guidance falls short of the Zacks Consensus Estimates and our...
By Zacks Investment Research - 7 weeks ago